Copyright © 2021 Pharmascimed. All Rights Reserved.
Novartis
Novartis acquires game-changing cardiovascular therapy
- February 25, 2019
- 0
Novartis has acquired rights to TQJ230 from Akcea Therapeutics, a novel cardiovascular drug that could become first-in-class and has the potential to treat million of patients. TQJ230 is based on the...
Read more
NICE rejects Novartis’ migraine drug for routine use
- January 9, 2019
- 0
The National Institute for Health Care and Excellent (NICE) has rejected Novartis' migraine drug Aimovig (erenumab) as preventative treatment for migraine in draft guidelines. The news comes after Aimovig was...
Read more